Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 2/20 | 0.52 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535507 | 0.85 | GAA (0.51) | MRGPRX4MAOB | |
| SCHEMBL20535609 | 0.84 | MAOB (0.55) | MRGPRX4IDO1AGXTMAOB | |
| SCHEMBL6827590 | 0.83 | MRGPRX4 (0.64) | MRGPRX4CYP3A4IDO1AGXTMAOB | |
| SCHEMBL20536357 | 0.82 | MRGPRX4 (0.47) | MRGPRX4CYP3A4IDO1AGXTMAOB | |
| SCHEMBL20535823 | 0.81 | CCR5 (0.49) | MRGPRX4IDO1AGXTMAOBMPO | |
| SCHEMBL20535652 | 0.79 | SMN1; SMN2 (0.47) | MRGPRX4ENPP2 | |
| SCHEMBL9550346 | 0.78 | RXRA (0.56) | MRGPRX4MAOB | |
| SCHEMBL5089248 | 0.77 | MAOB (0.67) | CYP3A4IDO1AGXTMAOBDHFR | |
| SCHEMBL4270131 | 0.77 | MAOB (0.54) | MRGPRX4IDO1AGXTMAOB | |
| SCHEMBL2565901 | 0.77 | GAA (0.50) | MRGPRX4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | MRGPRX4 1697/4885CYP3A4 2747/4885IDO1 2311/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | MRGPRX4 2982/4885CYP3A4 3619/4885IDO1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.